JONSON LIN: Open Payments
NPI 1114101995 · POMONA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$976 in 40 payments from 11 companies in 2025. Trend: 2023 $492 · 2024 $254 · 2025 $976
Food & beverage: $976
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $206 |
| ABBVIE INC. | 6 | $139 |
| Neurocrine BioSciences, Inc. | 6 | $129 |
| E.R. Squibb & Sons, L.L.C. | 4 | $97 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $92 |
| Alkermes, Inc. | 4 | $78 |
| Bausch Health US, LLC | 3 | $67 |
| Vanda Pharmaceuticals Inc. | 2 | $65 |
| Lundbeck LLC | 3 | $61 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
Products named: UZEDY, VRAYLAR, INGREZZA, COBENFY, CAPLYTA, REXULTI, APLENZIN, FANAPT.
Industry payments across CA — which companies pay providers there.
